Articles tagged with Clinical Studies
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
A new study suggests that a video game designed to raise teens' awareness of mental health issues can reduce symptoms of depression on par with in-school programs. The game, PlaySmart, was played by 269 students for up to six weeks, with significant reductions in symptoms reported after only six weeks.
A new book by University of Virginia Health System expert Daniel J. Cox outlines a practical alternative to medication for managing pre-diabetes and type 2 diabetes. The GEM program emphasizes smart eating, physical activity, and listening to the body to regulate blood sugar levels.
A new clinical trial at HonorHealth Research Institute uses a vaccine-based on immune system dendritic cells to fight advanced melanoma. The vaccine has shown promising results in treating refractory and unresectable cases of the disease, with a 10-fold increase in immune response.
The partnership aims to increase enrollment in clinical trials, making research opportunities more accessible to patients. UCCCC and Lilly will work together to open studies faster and connect more patients with research opportunities.
A new Cochrane review analyzed 11 studies involving 2,524 women undergoing embryo transfer, finding no reliable evidence that preparatory techniques improve IVF success rates. The techniques examined included straightening the utero-cervical angle and removing cervical mucus before transfer.
ISM8969/HT-001 is an orally available, brain-penetrant NLRP3 inhibitor with promising in vitro and in vivo profiles. The clinical trial aims to evaluate its safety, tolerability, and efficacy in patients with Parkinson's disease.
A pilot clinical trial of psilocybin-assisted therapy in veterans with severe PTSD found that 75% of participants were in remission one month after treatment, with no serious adverse events reported. The results suggest the protocol may be a game-changer for those struggling with treatment-resistant PTSD.
ISM6331, a novel pan-TEAD inhibitor, has received Fast Track Designation from the FDA for treating adult patients with unresectable malignant pleural mesothelioma. The treatment boasts synergistic anti-tumor effects and potential to overcome drug resistance as combination therapy.
The first patient has been enrolled in a global Phase 3 clinical trial evaluating Mocertatug Rezetecan, a novel B7-H4-targeted ADC, in platinum-resistant ovarian cancer. The study aims to determine whether this therapy can improve outcomes compared with standard chemotherapy.
A new study from Reichman University found that a short three-week digital training program improved motor function and brain activity in Parkinson's patients. The program, called DopApp, strengthened connectivity between brain regions responsible for movement and induced localized changes in neural circuits.
Exercise produces small improvements in pain and physical function for people with hip osteoarthritis, but those improvements may not be large enough to make a meaningful difference in daily life. Quality of life showed little to no improvement with exercise.
The Biggs Institute is leading a $2.5 million national, multi-site study to improve detection and diagnosis of dementia with Lewy bodies. The study will enroll 125 participants and evaluate multiple possible new tools and methods to accurately identify individuals who have accumulated abnormal alpha-synuclein in the brain.
A new cancer drug has shown promising results in a mesothelioma trial, controlling disease progression in 67% of patients. The drug targets the cancer's energy system by inhibiting a specific enzyme, causing oxidative stress that kills tumor cells.
A new study found that simple weekly electronic symptom check-ins with care teams significantly improves the quality of life for individuals undergoing treatment for advanced cancer. The benefits were notable among patient groups that historically faced barriers to care, including Black patients and those with less formal education.
A randomized clinical trial found that acupuncture to the ear (auriculotherapy) reduced migraine pain and improved its impact on daily life. The treatment showed a statistically significant improvement in oxygenation levels in the brain, but not a difference between the auriculotherapy and sham groups.
The University of California, San Francisco is launching a novel clinical trial to test a combination of therapies for the most common form of Alzheimer's disease. The trial will enroll up to 825 participants and test drugs that target both amyloid and tau proteins, with the goal of slowing disease progression.
A landmark study has shown that transplanting stem-cell derived dopamine progenitor cells into the brain is feasible and safe. Eight patients received the transplanted cell product, with no serious side effects observed during the first year of follow-up.
Rentosertib is a potentially first-in-class oral small-molecule inhibitor targeting TNIK for the treatment of idiopathic pulmonary fibrosis. The Phase III clinical trial will evaluate the efficacy and safety of once-daily Rentosertib administered over 52 weeks.
The FDA has granted early access to clinical trials for the new medication, allowing HonorHealth Research Institute to offer it to patients with previously treated metastatic pancreatic cancer. The drug has shown significant advancement in targeted therapy for pancreatic cancer, offering a median overall survival of 13.2 months.
Researchers will study blood samples and environmental exposures over 10 years to identify genetic, environmental, and cellular factors contributing to autoimmune diseases. The goal is to develop prevention strategies and treatments by understanding the earliest biological triggers of SARDs.
Researchers at the University of Calgary have developed a novel CAR T-cell therapy called GCAR1, showing strong preclinical and early clinical promise in treating sarcoma and other cancers. The therapy has been tested on two Canadian patients, with one patient experiencing significant prolongation of life expectancy by 18 months.
A large clinical trial found that an AI support tool improved the quality of clinical documentation and treatment planning, but did not significantly change short-term patient outcomes. The study involved over 9,600 patients in Kenya and used a randomized controlled design to test the effectiveness of the AI tool.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
A new study suggests that functional brain imaging can help guide accelerated transcranial magnetic stimulation (TMS) for depression, leading to improved symptoms and response rates. The approach uses resting-state functional connectivity analysis to identify individualized treatment targets.
Researchers at UCI Health have begun the world's first clinical trial for Huntington’s disease using neural stem cells. The phase 1b/2a trial aims to evaluate the safety and potential benefits of this innovative therapy, which could slow disease progression and reduce long-term care costs.
Researchers discovered Paneth cell metaplasia can act as a protective response in ulcerative colitis by promoting healing and regeneration of the intestinal lining through REG3A. However, persistent changes may still carry risks, including increased cancer risk.
Insilico Medicine has completed the first-in-human dosing of its AI-driven NLRP3 inhibitor ISM8969 in a Phase I clinical study. The trial aims to evaluate the safety, tolerability, and efficacy of ISM8969 in healthy participants and those at risk of cardiovascular disease.
Semmelweis University's new Anatomy & Innovation Center for Education and Research has hosted two NATO battlefield surgery courses, providing realistic environments for learning and practicing new procedures. The center aims to improve patient safety and quality of care through advanced technologies and hands-on training.
The NOVO EXPENDITURE trial investigates the effects of a hormone-based treatment on weight loss compared to a reduced-calorie diet. Participants will undergo extensive physiological testing, including metabolic chamber sessions and regular weigh-ins, to assess the treatment's impact on energy use and body weight.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Klick Labs is launching a series of clinical studies with Mayo Clinic exploring the use of novel vocal biomarkers in connection with Type 2 diabetes, hypertension, ovulation, and blood glucose. The research collaboration aims to leverage the voice's hidden properties to flag critical health issues and enhance patient care.
Dr. Jennifer Guida, a renowned researcher and program director, has been appointed as the first director of HonorHealth Research Institute's Division of Institutional Research. She will oversee the institute's clinical trials efforts, providing patients with pioneering treatments based on internal research discoveries.
The FDA has accepted Genentech's supplemental Biologic License Application for atezolizumab, supported by phase III ATOMIC trial results. The trial showed a 50% reduction in cancer recurrence or death and 86.3% disease-free survival rate.
A clinical trial tested four remote monitoring approaches against usual care and found that none outperformed usual care in reducing readmissions. The study highlights the importance of studying real-world care models to optimize outcomes.
A multinational clinical trial found that balanced crystalloid fluid and 0.9% saline are equally safe and effective for treating septic shock in children. The study enrolled over 9,000 children and showed no difference in outcomes between the two IV fluids.
Dr. Nageatte Ibrahim brings her expertise in immunotherapy and cancer drug development to HonorHealth Research Institute, focusing on advancing novel treatments and improving patient outcomes. The institute aims to develop collaborations with leading research centers worldwide to bring cutting-edge therapies to patients in need.
The FUTURE-D project combines data science with clinical expertise to identify warning signs of depression earlier, enabling more targeted interventions. Researchers will integrate longitudinal cohort data from the MACS and NESDA studies to better understand depressive disorders.
The FLOW trial shows that semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease. Health utility scores and self-rated general health scores improved with semaglutide, but declined with placebo.
Dr. Mina Sedrak has been selected to co-lead the Cancer in the Older Adult Committee of The Alliance for Clinical Trials in Oncology, focusing on improving care and outcomes for older adults with cancer. As a leading expert on aging and cancer, Sedrak aims to expand research on this population and address their unique needs.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
A nationwide study has compared two surgical approaches for treating Chiari malformation and syringomyelia, finding no difference in complication rates and clinical outcomes. Patients who underwent the more invasive procedure had greater improvement in their syringomyelia symptoms.
The UMass Center for Clinical and Translational Science has received a seven-year, $50 million grant from the NIH. The funding supports collaboration among researchers at multiple UMass campuses and clinical partners.
The Restore-1 clinical trial aims to modify the small intestine's lining with steam energy to restore natural blood-sugar control in patients with type 2 diabetes. The procedure, if successful, could prevent patients from advancing to insulin-dependent diabetes.
A new Cochrane review finds planned early birth for pregnant women with high blood pressure cuts maternal complications by nearly half and reduces the risk of stillbirth. The practice is found to be safe across both high- and low-income settings, without increasing the likelihood of caesarean section.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
Researchers found that stereotactic body radiotherapy (SBRT) improved progression-free survival by 15.6 months, compared to 20.6 months without targeted therapy. The treatment also showed no significant impact on quality-of-life measures.
Screening with a PSA blood test reduces prostate cancer deaths by approximately 2 for every 1,000 men screened. The review found that 500 men would need to be invited to screening to prevent one prostate cancer death.
A new study published in The Journal of Sexual Medicine found that combining phosphodiesterase type 5 inhibitors with selective oestrogen receptor modulators may slow or stop disease progression when given early. This combination resulted in improved penile curvature and reduced pain during erections compared to standard care.
A new study published in the Chinese Neurosurgical Journal found that most basilar trunk artery aneurysms can be treated effectively using endovascular techniques, resulting in encouraging long-term recovery rates. However, larger aneurysms pose higher treatment risks and are associated with complications and poorer outcomes.
A new study found that diaphragmatic dome height on chest X-rays is a practical prognostic marker for predicting long-term outcomes and respiratory-related deaths in lung cancer patients with breathing disorders. Lower DDH before surgery was associated with poorer survival rates.
A novel antibody, NG101, accelerates the regeneration of damaged spinal cord tissue by neutralizing a protein that blocks nerve fiber growth. This therapy enables new nerve fibers to form functional connections, allowing patients to become more independent and potentially recover arm and hand function.
A new national clinical trial investigates whether fewer invasive bladder exams can safely reduce discomfort and improve quality of life for patients with bladder cancer. Led by Dartmouth Cancer Center, the study aims to show that fewer procedures are just as effective at keeping patients healthy.
The PanAMP study assesses the impact of PanCystPro on clinicians' decision-making for patients with pancreatic cysts. The study aims to provide insights into surveillance and treatment strategies for those at higher risk for pancreatic cancer.
A new study published in Eye and Vision finds that one drop of low-dose atropine can produce daylong effects in managing myopia. The researchers found that the drop showed clear changes in pupil size and focusing ability, but no short-term structural effects on the eye.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Researchers agree on core elements of ACLF development, including chronic liver disease triggers, acute insult, and extrahepatic organ failure. A new three-stage mouse model supports testing of potential therapies, highlighting impaired liver regeneration as a key driver of disease progression.
The Patient-Centered Outcomes Research Institute (PCORI) has awarded funding for new patient-centered comparative clinical effectiveness research projects. These studies will examine different approaches to care across various health concerns, aiming to generate evidence for patients to make informed choices.
A new review proposes a prevention-focused framework for understanding Parkinson's disease risk, highlighting the role of early-life vulnerability, environmental exposures, and resilience factors. The study suggests that susceptibility to PD may begin earlier in life through interactions between biology and environment.